Introduction
Cancer is a major disease burden worldwide, with high morbidity and mortality rates compounded by the economic burden of maintaining patient quality-of-life and lengthening survival period. 1, 2 To date, many predictive biomarkers with excellent prognostic utility have been discovered for various cancers. Targeted molecular therapy and cancer immunotherapy have been introduced to improve disease management. [3] [4] [5] [6] One such biomarker is a cell surface protein known as trophoblast cell surface antigen 2 (TROP2), 7 also called "tacstd2", "m1s1 protein", "tumor-associated calcium signal transducer 2", "tumor-associated antigen ga733-1", "ga733-1 antigen", "membrane component 1 surface marker 1", "epithelial glycoprotein 1", and "gastrointestinal antigen 733-1". 8 This protein shows relatively low expression in normal epithelial cells and is overexpressed in various types of human cancers. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Overexpression of TROP2 in cancer has been linked to disease aggression and shorter overall survival (OS).
Several clinical studies have demonstrated that therapies targeting TROP2-benefited cancer patients by inhibiting TROP2 expression [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] and have explored this protein as a potential predictor of cancer prognosis. However, due to small sample size, the results were not categorically conclusive. 13, 15, 23, [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] The first meta-analysis about TROP2 was published 1 year ago, 47 which indicated that TROP2 overexpression was associated with poor survival in human solid tumors. Some new relevant studies have been published since then, therefore, we performed this meta-analysis to systematically review and gather more powerful evidence to verify the relationship between TROP2 overexpression and clinical characteristics/ prognosis in patients with a variety of human cancers.
Methods

Search strategy
Articles related to TROP2 and carcinomas were retrieved from online databases: Embase, PubMed, ISI Web of Science, China National Knowledge Infrastructure (CNKI), and WanFang Data Knowledge Service Platform (WanFang Data). The Medical Subject Headings (MeSH) search terms were as follows: "tacstd2" or "m1s1 protein" or "tumor-associated calcium signal transducer 2" or "trop2" or "tumor-associated antigen ga733-1" or "ga733-1 antigen" or "trop-2" or "trophoblast cell surface antigen 2" or "membrane component 1 surface marker 1" or "epithelial glycoprotein 1" or "gastrointestinal antigen 733-1" and "cancer" or "tumor" or "carcinoma" or "neoplasm". We additionally retrieved references cited in the articles and included them in the study. The last search was performed on September 23, 2017.
Selection criteria
Studies that 1) investigated the relationship between TROP2 and patient prognosis; 2) provided available data to obtain or calculate risk ratio (RR) or hazard ratio (HR) for survival and 95% confidence interval (CI); and 3) had clear statement about TROP2 expression state as "high" and "low" or "positive" and "negative" were included in this meta-analysis.
Exclusion criteria were (1) published letters, editorials, abstracts, reviews, case reports and expert opinions; (2) experiments not performed on patients; and (3) articles without the HRs and 95% CI or K-M survival curves about patients' prognostic outcomes.
Data extraction
The following data were extracted from each publication: first author, year of publication, country, tumor type, clinical stage, sample size, age of patients, analysis method, follow-up period, outcome, parameter cutoff values, survival analysis, estimates such as HRs or RRs concerning the overexpression of TROP2 in terms of OS, disease-free survival (DFS)/ progression-free survival (PFS), disease recurrence (DR), and patient clinical characteristics. The HRs or RRs and their 95% CIs were extracted from the original papers directly if available (23 articles, 25 studies). Otherwise, relevant data such as sample number in test groups, log-rank statistics, and p value were used to calculate the variable (3 studies [48] [49] [50] ). Alternatively, the approximate HRs (1 study 15 ) were calculated according to the Zhou ZR's statistical method from the Kaplan-Meier survival curves. 51 The Engauge Digitizer version 4.1 was used for this analysis.
Statistical analysis
The extracted HRs/RRs were summarized as pooled HR and 95% CI values, using Stata, version 12.0. The fixed-effects model was used at first to calculate the heterogeneity and construct forest plots. For inconsistency tests, I
2 > 50% and p < 0.05 were considered statistically significant. Larger values of I 2 indicated higher heterogeneity. The fixed-effects model was subsequently used when heterogeneity was not significant (<50%). 52 We conducted subgroup analysis and sensitivity analysis to compensate for statistical heterogeneity. Graphical funnel plots were generated, and Begg's test and Egger's test were performed to assess the extent of publication bias by visual inspection or by quantitative evaluation.
53,54
Results
Study selection and characteristics
As shown in Figure 1 , a total of 1,155 articles were identified initially. After excluding 515 duplicates, titles/abstracts of 640 studies were reviewed. Of these, 167 articles were not related to the research objective, 435 articles were not performed on patients and 3 were systematic reviews. Thirtyfive articles were reviewed further. Three articles were not available to get full text, and five papers did not provide applicable data for meta-analysis. We handpicked the remaining 27 articles eligible for this meta-analysis. The studies by Inamura estimated the roles of TROP2 in cancer prognosis among 3 different lung cancer subtypes (adenocarcinoma, squamous cell carcinoma, and high-grade neuroendocrine tumor), and thus it was regarded as 3 independent studies. 55 The main characteristics of these studies are presented in Table 1 . All included studies were published from 2006 to 2017. There were 17 studies from China, 5 from Japan, 3 from Austria, 3 from Italy, and 1 from South Korea. A total Relationship between the expression of TROP2 and patients' OS Our analysis revealed a positive link between TROP2 overexpression and OS (pooled HR: 1.84, 95% CI: 1.45-2.35), with heterogeneity (I 2 = 67.3%; p = 0.000), indicating that higher level of TROP2 expression could predict shorter OS outcomes ( Figure 2 and Table 2 ). In subgroup analysis according to geographical location, HRs were greater than 1.0 in the population from China, Austria, with low heterogeneity, in agreement with previous studies (China: I 2 = 43.0%, p = 0.044; Austria: 
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Prognostic role and clinical significance of TROP2 Italy were not statistically significant (Figure 2 ), the results of the sensitivity analysis showed that the association between TROP2 and OS was stable, and the studies by Ambrogi et al, 49 Inamura et al 55 affected results greatly ( Figure 3 ). After excluding these 2 studies (Ambrogi and Inamura (c)) one by one, the heterogeneity decreased significantly (without Ambrogi: I 2 = 51.8%, p = 0.002; without Ambrogi and Inamura (c): I 2 = 28.1%, p = 0.100) ( Figure 4A and B). The publication bias evaluation is shown in Figure 5 (Egger's test: p = 0.048; Begg's test: p = 0.217). According to Shi's conclusions, 65 we thought that there is no significant publication bias.
Relationship between TROP2 expression and patient outcomes
There were 6 studies, 5 studies, 4 studies, 3 studies, and one related to the association between TROP2 expression and DFS, PFS, DR, CSS, and DFS/PFS, respectively. We found that the overexpression of TROP2 was a potential negative 36 Chen et al (2013) 37 Fang et al (2009) 38 Guan et al (2015) 41 Jiang et al (2017) 48 Li (2017) 60 Lin et al (2013) 50 Liu et al (2013) 13 Ning (2012) 45 Wu (2012) 61 Xu (2009) 62 Xu et al (2016) 56 Zhao (2016) 63 Zhao (2015) Pak et al (2012) 15 Inamura et al (a) (2017) 55 Inamura et al (b) (2017) 55 Inamura et al (c) (2017) 55 Kobayashi et al (2010) 43 Ohmachi et al (2006) 46 Fong et al (2008) 39 Fong et al (2008) 
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Prognostic role and clinical significance of TROP2 34 Bignotti et al (2012) 35 Chen et al (2014) 36 Chen et al (2013) 37 Fang et al (2009) 38 Fong et al (2008) 39 Fong et al (2008) 40 Guan et al (2015) 41 Inamura et al (a) 2017 55 Inamura et al (b) 2017 55 Inamura et al (c) 2017 55 Jiang et al (2017) 48 Kobayashi et al (2010) 43 Li (2017) 60 Lin et al (2013) 50 Liu et al (2013) 13 Mühlmann et al (2008) 44 Ning (2012) 45 Ohmachi et al (2006) 46 Pak et al (2012) 15 Wu (2012) 61 Xu (2009) 62 Xu et al (2016) 56 Zhao (2016) 63 Zhao (2015) 34 Bignotti et al (2012) 35 Chen et al (2014) 36 Chen et al (2013) 37 Fang et al (2009) 38 Fong et al (2008) 39 Fong et al (2008) 40 Guan et al (2015) 41 Inamura (a) (2017) 55 Inamura (b) (2017) 55 Inamura (c) (2017) 55 Jiang et al (2017) 48 Kobayashi et al (2010) 43 Li (2017) 60 Lin et al (2013) 50 Liu et al (2013) 13 Mühlmann et al (2008) 44 Ning (2012) 45 Ohmachi et al (2006) 46 Pak et al (2012) 15 Wu (2012) 61 Xu et al (2016) 56 Zhao (2016) 63 Zhao (2015) 64 Xu (2009) ( Figure 6A ). The publication bias analyses were performed, and no significant publication bias was found (Egger's test: p = 0.297; Begg's test p = 0.624) ( Figure 6B ). 
Relationship between TROP2 overexpression and clinical characteristics
Discussion
This meta-analysis contained data from 4,852 participants, evaluated in 27 articles (29 studies). Overall analysis and subgroup analysis were performed. The results clearly showed 34 Bignotti et al (2012) 35 Chen et al (2014) 36 Chen et al (2013) 37 Fang et al (2009) 38 Fong et al (2008) 39 Fong et al (2008) 40 Guan et al (2015) 41 Inamura (a) (2017) 55 Inamura (b) (2017) 55 Jiang et al (2017) 48 Kobayashi et al (2010) 43 Li (2017) 60 Lin et al (2013) 50 Liu et al (2013) 13 Mühlmann et al (2008) 44 Ning (2012) 45 Ohmachi et al (2006) 46 Pak et al (2012) 15 Wu (2012) 61 Xu et al (2016) 56 Zhao (2016) 63 Zhao (2015) 64 Xu (2009) that overexpression of TROP2 is significantly associated with poor OS, DFS, PFS, as well as the following clinical characteristics: moderate/poor tumor differentiation, lymph node metastasis, the presence of distant metastasis, and advanced TNM stage. Although some significant heterogeneity was found, the association between TROP2 and cancers was stable, just as sensitivity analysis and publication bias evaluation showed. We found that the studies by Ambrogi et al 49 and Inamura et al 55 put forward opposite views from the other studies, then we checked them carefully and no obvious error or defect was found. That is why we made this meta-analysis due to the urgent need of further studies with larger sample sizes.
This meta-analysis has both strengths and limitations. A larger sample size compared to a previous study 47 (27 vs 16 articles, 4,852 vs 2,569 patients) powered the study effectively and increased the reliability of the results. However, most of the included papers are retrospective observational studies without control groups. In addition, there were inconsistencies among studies in defining important terms such as: "the overexpression of TROP2", "the TNM stage", "differentiation", and "the cut-off value for age". Another limitation of this study is that, in some cases, values were indirectly obtained from survival curves or were calculated using related data, probably resulting in some bias because of analytical errors. Furthermore, a wide range of the publication dates meant that other biases may have been introduced due to gradual improvements in detection techniques, surgical efficacy, safety, and medical treatment over time. These limitations were unavoidable and could only be addressed by performing more studies with larger sample sizes.
Currently, the mechanism of TROP2 signaling and its function remain uncertain. The proposed mechanisms of TROP2 action are as follows: regulating calcium levels via protein kinase C (PKC) mitogenic signaling pathway, modulating extracellular regulated protein kinases (ERK) signaling, decreasing cell adhesion to fibronectin via integrin pathway, regulating gene expression via intramembrane proteolysis, causing neuregulin 1 (NRG1) release, and activating the epidermal growth factor family receptor, ErbB3. 8 Studies in zebrafish and mice have elucidated the role of TROP2 in the development of lung, intestines, and kidney. 66, 67 These studies have revealed the role of TROP2 in promoting cell proliferation and organ development. A number of clinical studies overwhelmingly confirmed a strong association between TROP2 expression levels and tumor proliferation, aggressiveness, invasiveness, and metastasis, so they pointed out that TROP2 can be used as a biomarker for clinical diagnosis and to predict prognosis. 9, 31, 35, 37, 39, 42, 46, 68 Furthermore, recombinant antibodies against TROP2 have been used to treat cancers by inhibiting TROP2 expression or by destroying cancer cells directly. Results from such studies have confirmed the efficacy of TROP2 targeted therapies. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] However, normal-born TROP2-knockout mice can survive and grow to adulthood, which means that TROP2 may not be vital for organ and body development, or that its function can be taken over by other proteins. 69 In addition, one study has shown that tumorigenesis may result as a consequence of defective TROP2. 34 Bignotti et al (2012) 35 Fong et al (2008) 39 Liu et al (2013) 13 Ambrogi et al (2014) 49 Fang et al (2009) 38 Yuan (2015) 58 Zhang (2017) 57 Zhang (2017) 57 Chen et al (2014) 59 Bignotti et al (2010) 34 Bignotti et al (2012) 35 Guan et al (2015) 41 Muhlmann et al (2008) 44 Pak et al (2012) 15 Xu et al (2016) 56 Inamura (b) (2017) 55 Inamura (c) (2017) 55 36 Inamura (a) (2017) 55 Inamura (b) (2017) 55 Jiang et al (2017) 48 Li (2017) 60 Lin et al (2013) 50 Liu et al (2013) 13 Mühlmann et al (2008) 44 Ning (2012) 45 Ohmachi et al (2006) 46 Pak et al (2012) 15 Wu (2012) 61 Xu (2009) 62 Zhao (2016) 63 Zhao (2015) 64 Fong 39 Guan et al (2015) 41 Lin et al (2013) 50 Mühlmann et al (2008) 44 Zhao (2015) 34 Bignotti et al (2012) 35 Jiang et al (2017) 48 Kobayashi et al (2010) 43 Guan et al (2015) 41 Li (2017) 60 Lin et al (2013) 50 Mühlmann et al (2008) 44 Ohmachi et al (2006) 46 Wu (2012) 61 Xu (2009) 62 Xu et al (2016) 56 Zhao (2016) 63 Zhao (2015) 64 Fong et al (2008) 39 Fong 36 Guan et al (2015) 41 Fong et al (2008) 39 Fong et al (2008) 40 Li (2017) 60 Lin et al (2013) 50 Liu et al (2013) 13 Inamura (a) (2017) 55 Inamura (b) (2017) 55 Inamura (c) (2017) 55 Ning (2012) 45 Pak et al (2012) 15 Wu (2012) 61 Zhao (2016) 63 Zhao (2015) 
Conclusion
Thus, the function and the mechanisms of action of TROP2 are not clear yet, while the relationship between TROP2 and cell proliferation is complex, possibly determined by tissue type and context. 8, 55 Further research studies with larger sample sizes should be conducted to learn and confirm its role in cancer occurrence, development, and mechanism of action. In conclusion, the expression of TROP2 is associated with cancer disease, maybe a potential diagnostic indicator and prognostic biomarker.
